These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1284 related articles for article (PubMed ID: 17606310)

  • 21. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
    Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.
    Kim H; Kwon YM; Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2006 Sep; 107(5):1042-9. PubMed ID: 16888795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
    Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
    Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
    Gu J; Berman D; Lu C; Wistuba II; Roth JA; Frazier M; Spitz MR; Wu X
    Clin Cancer Res; 2006 Dec; 12(24):7329-38. PubMed ID: 17189404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.
    Chang MS; Uozaki H; Chong JM; Ushiku T; Sakuma K; Ishikawa S; Hino R; Barua RR; Iwasaki Y; Arai K; Fujii H; Nagai H; Fukayama M
    Clin Cancer Res; 2006 May; 12(10):2995-3002. PubMed ID: 16707594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.